Guillaume Poncet-Montange

Guillaume Poncet-Montange, Pharm.D., Ph.D.

Guillaume Poncet-Montange

Guillaume Poncet-Montange is a senior group leader in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. He leads the structural biology group and a multi-disciplinary therapeutic project involving 50 scientists through a collaboration with Calico and AbbVie. Poncet-Montange is a pharmaceutical scientist with a passion for drug discovery, and he worked in numerous therapeutic areas including neurodegenerative diseases, oncology (epigenetics), and infectious diseases.

Prior to joining the Broad Institute in 2018, Poncet-Montange used his background in pharmaceutical research and structural biology to develop a consistent track record of collaborations and scientific discoveries at a start-up company, Orthogon Therapeutics, LLC, and at the MD Anderson Cancer Center Institute for Applied Cancer Science.A noteworthy achievement includes Poncet-Montange’s contribution to develop IACS-9571, the first-in-class inhibitor of TRIM24. He has been awarded patents with the Pasteur Institute.

Poncet-Montange’s core interests include structure-function of therapeutic targets and structure-based drug design, leveraging x-ray crystallography, cryo-EM, cheminformatics, bioinformatics, biophysics, biochemistry, and innovative drug discovery technologies.

Poncet-Montange holds a Pharm.D. from Université Paul Sabatier Toulouse III and a Ph.D. in structural biology from the University of Montpellier 1. His postdoctoral research was undertaken first at the University of Montpellier 2 and subsequently at the University of California, San Francisco in the lab of Nobel Laureate Stanley Prusiner.

Contact Guillaume Poncet-Montange via email at

July 2022